Home › Companies › AGIOS PHARMACEUTICALS INC. › 2023-2024

AGIOS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and AGIOS PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-20 (Item 5.07 on EDGAR). Page generated 04 October 2026.

6Ballot items
204Asset managers
1,567Fund votes
2024-06-20Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AGIOS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by AGIOS PHARMACEUTICALS INC.

These tallies are AGIOS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AGIOS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-06-20
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Kaye Foster	45,821,431	--	--	5,297,937	1,255,248	Majority: yes
Elect Director: Maykin Ho, Ph.D.	46,670,795	--	--	4,448,573	1,255,248	Majority: yes
Elect Director: Jeffrey Capello	47,839,112	--	--	3,280,256	1,255,248	Majority: yes
Elect Director: Catherine Owen	45,595,875	--	--	5,523,493	1,255,248	Majority: yes
2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.	47,985,871	3,120,093	13,404	--	1,255,248	Passed
3. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.	52,301,377	70,843	2,396	--	0	Passed

Source: AGIOS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-20 — read the filing on EDGAR.

How asset managers voted at the AGIOS PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 204 asset managers that disclosed a AGIOS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. TO VOTE, ON AN ADVISORY BASIS, TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESCompany result: Passed

Combines 7 wordings of this item as funds reported it.

94% Passed · of votes cast

FOR 94%

FOR: 47,985,871AGAINST: 3,120,093

AGIOS PHARMACEUTICALS INC.’s own tally for this item (“2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”): 47,985,871 for, 3,120,093 against — passed, per its Form 8-K filed 2024-06-20 (Item 5.07). Of all 56,751,511 outstanding shares: 85% for, 5% against (90% of the company cast a for/against vote).

The 203 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 96%

FOR: 96.0%AGAINST: 4.0%

Largest asset managers voting on “TO VOTE, ON AN ADVISORY BASIS, TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at AGIOS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	6,433,356	0	For
T. Rowe Price	5,068,145	0	For
State Street	4,528,349	0	For
FARALLON CAPITAL MANAGEMENT LLC	4,220,024	0	For
BlackRock	3,886,049	0	For
JPMorgan	3,300,709	0	For
Dimensional	2,433,355	0	For
ARMISTICE CAPITAL, LLC	1,844,938	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	1,765,115	0	For
Delaware/Macquarie	1,611,058	0	For
ArrowMark Colorado Holdings LLC	1,370,496	0	For
Fidelity	1,366,434	0	For
Rock Springs Capital Management LP	1,294,687	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,284,370	0	For
BNP Paribas Asset Management Holding S.A.	0	1,108,613	Against
Charles Schwab	887,616	0	For
Vestal Point Capital, LP	625,000	0	For
GW&K Investment Management, LLC	560,499	3,400	For
PICTET ASSET MANAGEMENT SA	488,949	0	For
Northern Trust	459,139	35	For
Eagle Health Investments LP	330,830	0	For
Citadel	311,041	0	For
Goldman Sachs	296,625	0	For
Fisher Asset Management, LLC	288,974	0	For
Prudential/PGIM	280,453	0	For

Showing the 25 largest of 203 asset managers. See all 203 in the interactive database.

2. To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Catherine Owen

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 45,595,875WITHHELD: 5,523,493

AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Catherine Owen”): 45,595,875 for, 5,523,493 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 56,751,511 outstanding shares: 80% for, 10% withheld (90% of the company cast a for/withheld vote).

The 69 asset managers below cast 100% of the shares they voted on this item FOR (18,259,940 for, 0 against).

FOR 85%ABSTAIN 15%

FOR: 18,259,940 (85.3%)ABSTAIN: 3,150,360 (14.7%)

Largest asset managers voting on “To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a thr” at AGIOS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	6,334,660	0	For
Dimensional	2,254,003	0	For
T. Rowe Price	622,367	1,536,244	Abstain
BlackRock	2,043,012	0	For
State Street	1,715,919	0	For
Delaware/Macquarie	1,611,058	0	For
Fidelity	158,362	1,203,107	Abstain
JPMorgan	1,187,008	0	For
Charles Schwab	443,808	0	For
AIG/SunAmerica	195,717	0	For
MERIDIAN FUND INC	187,373	0	For
Equitable	85,297	75,978	For
TIAA	154,678	0	For
Prudential/PGIM	78,260	64,828	For
First Trust	131,432	0	For
Direxion Shares ETF Trust	115,183	0	For
Brighthouse	62,102	46,240	For
QUANTITATIVE MASTER SERIES LLC	103,537	0	For
Goldman Sachs	96,035	0	For
AMG FUNDS	0	93,104	Abstain
American Century	82,007	0	For
Columbia Threadneedle	69,358	0	For
John Hancock	26,502	33,034	Abstain
Lincoln Financial	54,469	0	For
ProShares	46,735	0	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

3. To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Jeffrey Capello

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 47,839,112WITHHELD: 3,280,256

AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jeffrey Capello”): 47,839,112 for, 3,280,256 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 56,751,511 outstanding shares: 84% for, 6% withheld (90% of the company cast a for/withheld vote).

The 69 asset managers below cast 100% of the shares they voted on this item FOR (19,726,761 for, 0 against).

FOR 92%8%

FOR: 19,726,761 (92.1%)ABSTAIN: 1,683,539 (7.9%)

Largest asset managers voting on “To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a thr” at AGIOS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	6,334,660	0	For
Dimensional	2,254,003	0	For
T. Rowe Price	622,367	1,536,244	Abstain
BlackRock	2,043,012	0	For
State Street	1,715,919	0	For
Delaware/Macquarie	1,611,058	0	For
Fidelity	1,361,469	0	For
JPMorgan	1,187,008	0	For
Charles Schwab	443,808	0	For
AIG/SunAmerica	195,717	0	For
MERIDIAN FUND INC	187,373	0	For
Equitable	149,737	11,538	For
TIAA	154,678	0	For
Prudential/PGIM	114,560	28,528	For
First Trust	131,432	0	For
Direxion Shares ETF Trust	115,183	0	For
Brighthouse	62,102	46,240	For
QUANTITATIVE MASTER SERIES LLC	103,537	0	For
Goldman Sachs	96,035	0	For
AMG FUNDS	93,104	0	For
American Century	82,007	0	For
Columbia Threadneedle	69,358	0	For
John Hancock	26,502	33,034	Abstain
Lincoln Financial	54,469	0	For
ProShares	46,735	0	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

4. To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Kaye Foster

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 45,821,431WITHHELD: 5,297,937

AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kaye Foster”): 45,821,431 for, 5,297,937 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 56,751,511 outstanding shares: 81% for, 9% withheld (90% of the company cast a for/withheld vote).

The 69 asset managers below cast 100% of the shares they voted on this item FOR (18,981,913 for, 0 against).

FOR 89%11%

FOR: 18,981,913 (88.7%)ABSTAIN: 2,428,387 (11.3%)

Largest asset managers voting on “To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a thr” at AGIOS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	6,334,660	0	For
Dimensional	2,254,003	0	For
T. Rowe Price	0	2,158,611	Abstain
BlackRock	2,043,012	0	For
State Street	1,715,919	0	For
Delaware/Macquarie	1,611,058	0	For
Fidelity	1,361,469	0	For
JPMorgan	1,187,008	0	For
Charles Schwab	443,808	0	For
AIG/SunAmerica	195,717	0	For
MERIDIAN FUND INC	187,373	0	For
Equitable	85,297	75,978	For
TIAA	154,678	0	For
Prudential/PGIM	114,560	28,528	For
First Trust	131,432	0	For
Direxion Shares ETF Trust	115,183	0	For
Brighthouse	62,102	46,240	For
QUANTITATIVE MASTER SERIES LLC	103,537	0	For
Goldman Sachs	96,035	0	For
AMG FUNDS	93,104	0	For
American Century	82,007	0	For
Columbia Threadneedle	69,358	0	For
John Hancock	26,502	33,034	Abstain
Lincoln Financial	54,469	0	For
ProShares	46,735	0	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

5. To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Maykin Ho, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 46,670,795WITHHELD: 4,448,573

AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Maykin Ho, Ph.D.”): 46,670,795 for, 4,448,573 withheld, per its Form 8-K filed 2024-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 56,751,511 outstanding shares: 82% for, 8% withheld (90% of the company cast a for/withheld vote).

The 69 asset managers below cast 100% of the shares they voted on this item FOR (19,039,954 for, 0 against).

FOR 89%11%

FOR: 19,039,954 (88.9%)ABSTAIN: 2,370,346 (11.1%)

Largest asset managers voting on “To elect each of the four Class II director nominees set forth in the Proxy Statement, each to serve for a thr” at AGIOS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	6,334,660	0	For
Dimensional	2,254,003	0	For
T. Rowe Price	0	2,158,611	Abstain
BlackRock	2,043,012	0	For
State Street	1,715,919	0	For
Delaware/Macquarie	1,611,058	0	For
Fidelity	1,361,469	0	For
JPMorgan	1,187,008	0	For
Charles Schwab	443,808	0	For
AIG/SunAmerica	195,717	0	For
MERIDIAN FUND INC	187,373	0	For
Equitable	85,297	75,978	For
TIAA	154,678	0	For
Prudential/PGIM	114,560	28,528	For
First Trust	131,432	0	For
Direxion Shares ETF Trust	115,183	0	For
Brighthouse	62,102	46,240	For
QUANTITATIVE MASTER SERIES LLC	103,537	0	For
Goldman Sachs	96,035	0	For
AMG FUNDS	93,104	0	For
American Century	82,007	0	For
Columbia Threadneedle	69,358	0	For
John Hancock	26,502	33,034	Abstain
Lincoln Financial	54,469	0	For
ProShares	46,735	0	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

6. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDCompany result: Passed

Combines 4 wordings of this item as funds reported it.

99.8% Passed · of votes cast

FOR 99.8%

FOR: 52,301,377AGAINST: 70,843

AGIOS PHARMACEUTICALS INC.’s own tally for this item (“3. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”): 52,301,377 for, 70,843 against — passed, per its Form 8-K filed 2024-06-20 (Item 5.07). Of all 56,751,511 outstanding shares: 92% for, 0.2% against (92% of the company cast a for/against vote).

The 69 asset managers below cast 99.8% of the shares they voted on this item FOR (21,387,942 for, 22,358 against).

FOR 99.8%

FOR: 21,387,942 (99.9%)AGAINST: 22,358 (0.1%)

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm f” at AGIOS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Vanguard	6,334,660	For
Dimensional	2,254,003	For
T. Rowe Price	2,158,611	For
BlackRock	2,043,012	For
State Street	1,715,919	For
Delaware/Macquarie	1,611,058	For
Fidelity	1,361,469	For
JPMorgan	1,187,008	For
Charles Schwab	443,808	For
AIG/SunAmerica	195,717	For
MERIDIAN FUND INC	187,373	For
Equitable	161,275	For
TIAA	154,678	For
Prudential/PGIM	143,088	For
First Trust	131,432	For
Direxion Shares ETF Trust	115,183	For
Brighthouse	108,342	For
QUANTITATIVE MASTER SERIES LLC	103,537	For
Goldman Sachs	96,035	For
AMG FUNDS	93,104	For
American Century	82,007	For
Columbia Threadneedle	69,358	For
John Hancock	59,536	For
Lincoln Financial	54,469	For
ProShares	46,735	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

Largest AGIOS PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of AGIOS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 56,751,511 shares outstanding at the time of that meeting.

Top AGIOS PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	11.34%
2	T. Rowe Price	8.93%
3	State Street	7.98%
4	FARALLON CAPITAL MANAGEMENT LLC	7.44%
5	BlackRock	6.85%
6	JPMorgan	5.82%
7	Dimensional	4.29%
8	ARMISTICE CAPITAL, LLC	3.25%
9	MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	3.11%
10	Delaware/Macquarie	2.84%

Reported AGIOS PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

AGIOS PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	9.88%	13F
BlackRock	8.01%	13F
BB Biotech AG	7.05%	13G
State Street	5.53%	13F
Dimensional Fund Advisors	4.54%	13F
T. Rowe Price	3.55%	13F
Geode Capital	2.26%	13F
Citadel Advisors	1.84%	13F
Goldman Sachs	1.42%	13F
Northern Trust	1.04%	13F

Percentages above are of 56,751,511 shares outstanding, as reported by AGIOS PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AGIOS PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At AGIOS PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-20, in the 2023-2024 proxy season, 204 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,567 separate fund positions. On the most widely held item on that ballot — TO VOTE, ON AN ADVISORY BASIS, TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — the proposal passed with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AGIOS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-20.

AGIOS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.